A detailed history of American International Group, Inc. transactions in Inhibrx, Inc. stock. As of the latest transaction made, American International Group, Inc. holds 16,926 shares of INBX stock, worth $239,841. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,926
Previous 17,071 0.85%
Holding current value
$239,841
Previous $648,000 8.8%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$32.76 - $39.56 $4,750 - $5,736
-145 Reduced 0.85%
16,926 $591,000
Q4 2023

Feb 13, 2024

SELL
$14.5 - $38.0 $1,000 - $2,622
-69 Reduced 0.4%
17,071 $648,000
Q3 2023

Nov 13, 2023

BUY
$15.75 - $26.31 $9,607 - $16,049
610 Added 3.69%
17,140 $314,000
Q2 2023

Aug 04, 2023

BUY
$16.96 - $27.82 $13,669 - $22,422
806 Added 5.13%
16,530 $429,000
Q1 2023

May 12, 2023

BUY
$18.45 - $27.14 $5,774 - $8,494
313 Added 2.03%
15,724 $296,000
Q4 2022

Feb 10, 2023

BUY
$20.18 - $33.33 $31,319 - $51,728
1,552 Added 11.2%
15,411 $379,000
Q3 2022

Nov 14, 2022

BUY
$11.58 - $24.73 $2,258 - $4,822
195 Added 1.43%
13,859 $249,000
Q2 2022

Aug 12, 2022

SELL
$8.52 - $25.26 $1,661 - $4,925
-195 Reduced 1.41%
13,664 $155,000
Q1 2022

May 13, 2022

SELL
$19.89 - $43.18 $19,412 - $42,143
-976 Reduced 6.58%
13,859 $309,000
Q4 2021

Feb 11, 2022

SELL
$26.75 - $46.02 $11,850 - $20,386
-443 Reduced 2.9%
14,835 $648,000
Q3 2021

Nov 12, 2021

SELL
$25.18 - $37.81 $9,165 - $13,762
-364 Reduced 2.33%
15,278 $509,000
Q2 2021

Aug 13, 2021

BUY
$14.69 - $27.52 $160,194 - $300,105
10,905 Added 230.21%
15,642 $430,000
Q1 2021

May 07, 2021

BUY
$16.27 - $41.26 $195 - $495
12 Added 0.25%
4,737 $95,000
Q4 2020

Feb 12, 2021

BUY
$15.96 - $50.0 $75,411 - $236,250
4,725 New
4,725 $156,000

Others Institutions Holding INBX

About Inhibrx, Inc.


  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $553M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.